Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Xenon Pharmaceuticals Inc | XENE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 36.17 | 04:00:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 36.17 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 24.94 - 41.39 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 36.17 | USD |
Xenon Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.28B | 63.04M | 62.31M | $ 9.43M | $ -7.97M | -2.04 | -19.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 0.90% |
Xenon Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XENE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 33.91 | 36.58 | 32.94 | 34.82 | 492,314 | 2.26 | 6.66% |
| 1 Month | 40.00 | 40.00 | 32.64 | 35.36 | 459,981 | -3.83 | -9.58% |
| 3 Months | 37.26 | 41.25 | 32.64 | 36.94 | 408,852 | -1.09 | -2.93% |
| 6 Months | 35.86 | 41.25 | 31.79 | 36.66 | 383,286 | 0.31 | 0.86% |
| 1 Year | 30.21 | 41.39 | 24.94 | 34.59 | 430,053 | 5.96 | 19.73% |
| 3 Years | 10.94 | 41.39 | 9.32 | 28.93 | 450,322 | 25.23 | 230.62% |
| 5 Years | 4.90 | 41.39 | 4.50 | 25.45 | 335,579 | 31.27 | 638.16% |
Xenon Pharmaceuticals Description
| Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |